- Home
- XOMAP vs SBAC Comparison
XOMAP vs SBAC Comparison
Compare XOMAP & SBAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- SBAC
- Stock Information
- Founded
- XOMAP N/A
- SBAC 1989
- Country
- XOMAP United States
- SBAC United States
- Employees
- XOMAP 13
- SBAC N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- SBAC Real Estate Investment Trusts
- Sector
- XOMAP Health Care
- SBAC Real Estate
- Exchange
- XOMAP Nasdaq
- SBAC Nasdaq
- Market Cap
- XOMAP N/A
- SBAC N/A
- IPO Year
- XOMAP N/A
- SBAC 1999
- Fundamental
- Price
- XOMAP $25.95
- SBAC $229.06
- Analyst Decision
- XOMAP
- SBAC Buy
- Analyst Count
- XOMAP 0
- SBAC 14
- Target Price
- XOMAP N/A
- SBAC $252.14
- AVG Volume (30 Days)
- XOMAP N/A
- SBAC 1.2M
- Earning Date
- XOMAP N/A
- SBAC 04-28-2025
- Dividend Yield
- XOMAP N/A
- SBAC 1.94%
- EPS Growth
- XOMAP N/A
- SBAC 50.54
- EPS
- XOMAP N/A
- SBAC 6.94
- Revenue
- XOMAP N/A
- SBAC $2,679,634,000.00
- Revenue This Year
- XOMAP N/A
- SBAC $3.48
- Revenue Next Year
- XOMAP N/A
- SBAC $4.90
- P/E Ratio
- XOMAP N/A
- SBAC $33.01
- Revenue Growth
- XOMAP N/A
- SBAC N/A
- 52 Week Low
- XOMAP N/A
- SBAC $183.64
- 52 Week High
- XOMAP N/A
- SBAC $252.64
- Technical
- Relative Strength Index (RSI)
- XOMAP 52.85
- SBAC 61.32
- Support Level
- XOMAP $24.96
- SBAC $221.88
- Resistance Level
- XOMAP $26.10
- SBAC $234.85
- Average True Range (ATR)
- XOMAP 0.38
- SBAC 8.92
- MACD
- XOMAP 0.03
- SBAC 0.98
- Stochastic Oscillator
- XOMAP 76.74
- SBAC 82.68
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.